qwertyuiopasdfghjklzxcvbnmqw ertyuiopasdfghjklzxcvbnmqwert yuiopasdfghjklzxcvbnmqwertyui opasdfghjklzxcvbnmqwertyuiopa sdfghjklzxcvbnmqwertyuiopasdf

Size: px
Start display at page:

Download "qwertyuiopasdfghjklzxcvbnmqw ertyuiopasdfghjklzxcvbnmqwert yuiopasdfghjklzxcvbnmqwertyui opasdfghjklzxcvbnmqwertyuiopa sdfghjklzxcvbnmqwertyuiopasdf"

Transcription

1 qwertyuiopasdfghjklzxcvbnmqw ertyuiopasdfghjklzxcvbnmqwert yuiopasdfghjklzxcvbnmqwertyui opasdfghjklzxcvbnmqwertyuiopa Shahin Gharakhanian MD sdfghjklzxcvbnmqwertyuiopasdf Publications & Conference Presentations 6/1/2013 ghjklzxcvbnmqwertyuiopasdfghj Updated 06/2013 klzxcvbnmqwertyuiopasdfghjklz xcvbnmqwertyuiopasdfghjklzxcv bnmqwertyuiopasdfghjklzxcvbn mqwertyuiopasdfghjklzxcvbnmq wertyuiopasdfghjklzxcvbnmqwe rtyuiopasdfghjklzxcvbnmqwerty uiopasdfghjklzxcvbnmqwertyuio pasdfghjklzxcvbnmqwertyuiopas dfghjklzxcvbnmqwertyuiopasdfg

2 Page1 CONTRIBUTIONS TO BOOKS GHARAKHANIAN S, ROZENBAUM W. Atteintes viscérales diverses dans l infection par le VIH. In: SIDA et infection VIH. MONTAGNIER L, ROZENBAUM W, GLUCKMAN JC (EDITORS), Paris : Médecine-Sciences Flammarion 1989 ; GHARAKHANIAN S, ROZENBAUM W. Pneumocystis carinii pneumonia in France In: AIDS in the World. MANN J, TARANTOLA DJM, NETTER T (EDITORS) Cambridge (Mass.): Harvard University Press, 1992 ;

3 Page2 CONFERENCE PRESENTATIONS < M O Z A F A R I A N G, S I O S H A N S I P, K A M A L - H E D A Y A T D, G H A R A K H A N I A N S. Quantitative analysis of magnesium and other trace elements in diabetics. 6 th Asia & Oceania Congress of Endocrinology, Singapore, January 1978 (abstract 159). ROZENBAUM W, BRUCKER G, DUFLO B, GHARAKHANIAN S, STENBERG M, GENTILINI M. Treatment of AIDS-related Kaposi s Sarcoma by alpha-2 recombinant Interferon. II International Conference on AIDS, Paris, June 1986 (abstract 33). POLLAK M, GHARAKHANIAN S, ROZENBAUM W, VIALLEFOND A, AIME F. An unspeakable disease. Self-isolation of HIV infected patients as a result of conflicting aspirations. III International Conference on AIDS, Washington, June 1987 (abstract ). ROZENBAUM W, GHARAKHANIAN S, DUFLO B, STENBERG M, BRUCKER G, GENTILINI M. Long term follow-up of 82 patients treated by recombinant alpha 2 interferon in AIDS related Kaposi s sarcoma. III International Conference on AIDS, Washington, June 1987 (abstract ). BARRE-SINOUSI F, REY F, GHARAKHANIAN S, OLIVIER-HENRY F, ROZENBAUM W, CHERMANN JC. Correlation between antibody response to HIV antigen, neutralizing antibody titers and clinical status. III International Conference on AIDS, Washington, June 1987 (abstract ). ROZENBAUM W, BUISSON M, TAMADON A, GHARAKHANIAN S, SEIGNEURIN JM. Epstein-Barr virus antibody pattern and clinical issue of HIV infection. European Conference on Clinical Aspects of HIV infection, Brussels, December 1987 (abstract 5).

4 Page3 BOURNERIAS I, BOISNIC S, PATEY O, GHARAKHANIAN S, DUFLO B, GENTILINI M. Lésions cutanées à cytomégalovirus chez deux patients atteints de SIDA. Journées dermatologiques, Paris, March 1988 (abstract 13; 176). ROZENBAUM W, GHARAKHANIAN S, CARDON B, DUVAL E, NAVARETTE MS, COULAUD JP. HIV transmission by oral sex. IV International Conference on AIDS, Stockholm, June 1988 (abstract 4562). ROZENBAUM W, GHARAKHANIAN S, NAVARETTE MS, DJURIC M, CHAMBARD F, LEMBERZSKI G, COULAUD JP.Role of outpatient care in the management of HIV infected patients. IV International Conference on AIDS, Stockholm, June 1988 (abstract 9039). GHARAKHANIAN S, CARDON B, NAVARETTE MS, ROZENBAUM W. Length of survival of 100 patients with AIDS-related Kaposi s sarcoma (KS) treated with recombinant alpha-2 Interferon. IV International Conference on AIDS, Stockholm, June 1988 (abstract 3514). BOURNERIAS I, PATEY O, BOISNIC S, GHARAKHANIAN S, DUFLO B, GENTILINI M. Unusual cutaneous cytomegalovirus involvement in two AIDS patients. IV International Conference on AIDS, Stockholm, June 1988, (abstract 7623). ROZENBAUM W, GHARAKHANIAN S, ROUZIOUX C, DE SAHB R, BUGARD M, CARDON B. HIV-Antigenemia in patients with AIDS-related Kaposi s Sarcoma treated with recombinant A-2 Interferon. V International Conference on AIDS, Montreal, June 1989 (abstract T.B.P. 283). ROZENBAUM W, GHARAKHANIAN S, ZAZOUN L, VASEGHI M, DE SAHB R, THOMSON M. Efficacy and toxicity of Ganciclovir maintenance treatment in AIDS-related CMV retinitis. V International Conference on AIDS, Montreal, June 1989 (abstract M.B.P. 132). NAVARETTE MS, GHARAKHANIAN S, CARDON B, ROZENBAUM W. Vitamin B12 supplements in patients treated with Zidovudine. V International Conference on AIDS, Montreal, June 1989 (abstract T.B.P. 307). GHARAKHANIAN S, DE SAHB R, VASEGHI M, CARDON B, ROZENBAUM W. Evaluation of the association of Zidovudine and Vinblastine in Treatment of AIDS-related Kaposi s Sarcoma. V International Conference on AIDS, Montreal, June 1989 (abstract M.B.P.) 368. ROZENBAUM W, GHARAKHANIAN S, CARDON B, NAVARETTE MS, DE SAHB R. Interferon in AIDS associated Kaposi s Sarcoma. International Dermatology Symposium, Berlin (west), October 1989 (abstract ).

5 Page4 LEHOANG P, MARCEL P, ROBINET M, ZAZOUN L, GIRARD B, CCOCHEREAU I, MATHERON S, KATLAMA C, ROZENBAUM W, SALMON D, SAIMOT AG, DOHIN E, GHARAKHANIAN S, PERRONNE C, COULAUD JP, GENTILINI M, VILDE JL, REGNIER B, ROUSSELIE F. Activity of Foscarnet (PFA) and Ganciclovir (DHPG) in CMV retinitis in AIDS. 29 th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC), Houston, October 1989 (abstract ) ROZENBAUM W, KADIVAR M, GHARAKHANIAN S, CANO C, DIAS TAVARES M, CARDON B. Trimethoprim-Sulfamethoxazole vs Pentamidine inhalations for primary prophylaxis of pneumocystis carinii Pneumonia. VI International Conference on AIDS, San Francisco, June 1990 (abstract 2085). CHRISTEFF N, KADIVAR M, GHARAKHANIAN S, DIAS TAVARES M, ROZENBAUM W, NUNEZ E. Steroid variations in different stages of HIV-disease. VI International Conference on AIDS, San Francisco, June 1990 (abstract F.B. 526). MATHERON S, DOURNON E, GHARAKHANIAN S, LEPORT C, DE TRUCHIS P, GAUDEBOUT C. Prevalence of toxoplasmosis in 365 AIDS and ARC patients before and during Zidovudine treatment. VI International Conference on AIDS, San Francisco, June 1990 (abstract Th.B. 476). SIBONY M, WECHLER J, BOURNERIAS I, GHARAKHANIAN S, FRAITAG S, ROUJEAU JC, REVUZ J. Angiomatose bacillaire chez un sujet atteint d immunodépression acquise. Journées de Pathologie, Paris, December 1990 (abstract ) BENJELLOUN N, ANKRI A, GHARAKHANIAN S, ABUAF N. Anticardiolipin and lupus-type anticoagulant antibodies in HIV infected patients. Joint meeting : Société Française d Immunologie/Nederlandse Vereniging voor Immunologie, Paris, September 1990 (abstract P2-94).

6 Page5 COSNES J, BEAUGERIE L, LAMY P, BELLANGER J, GHARAKHANIAN S, GENDRE JP, LE QUINTREC Y. Résultats de la nutrition entérale dans le SIDA avec atteinte digestive. 10 ème symposium of the Société Française de Nutrition Entérale et Parentale, Grenoble 1990, (abstract ). BEAUGERIE L, COSNES J, LAMY P, BELLANGER J, GHARAKHANIAN S, GENDRE JP, LE QUINTREC Y. Etude de retentissement nutritionnel de la malabsorption dans la diarrhée chronique du SIDA. 10th symposium of the Société Française de Nutrition Entérale et Parentale, Grenoble 1990 (abstract ). COSNES J, BEAUGERIE L, LAMY P, BELLANGER J, GHARAKHANIAN S, GENDRE JP, LE QUINTREC Y, ROZENBAUM W. Résultats de la nutrition entérale dans le SIDA avec atteinte digestive. Journées Francophones de Pathologie Digestive, Montpellier, March (abstract: Gastroentérologie Clinique et Biologique 1991; 15: A54). PODEVIN PH, BEAUGERIE L, GHARAKHANIAN S, FRITSCH J, COSNES J, GENDRE JP, LE QUINTREC Y, ROZENBAUM W. Cholestases majeures au cours du SIDA : les causes sont multiples. Journées Francophones de Pathologie Digestive, Montpellier, March (abstract: Gastroentérologie Clinique et Biologique 1991; 15: A262). LAMY PH, BEAUGERIE L, GHARAKHANIAN S, FRITSCH J, GENDRE JP, ETIENNE JP, ROZENBAUM W, LE QUINTREC Y.Cholangiographie retrograde : quelle place dans la cholangite du SIDA? Journées Francophones de Pathologie Digestive, Montpellier, March (abstract: Gastroentérologie Clinique et Biologique 1991; 15: A205). BEAUGERIE L, LAMY PH, BELLANGER J, GHARAKHANIAN S, COSNES J, GENDRE JP, LE QUINTREC Y, ROZENBAUM W. Malabsorption inexpliquée au cours de la diarrhée chronique du SIDA : à propos de 8 cas. Journées Francophones de Pathologie Digestive, Montpellier, March (abstract: Gastroentérologie Clinique et Biologique 1991; 15: A157). BEAUGERIE L, COSNES J, LAMY PH, BELLANGER J, GHARAKHANIAN S, GENDRE JP, LE QUINTREC Y, ROZENBAUM W.Etude de la fréquence et du retentissement nutritionnel de la malabsorption dans la diarrhée chronique du SIDA. Journées Francophones de Pathologie Digestive, Montpellier, March (abstract: Gastroentérologie Clinique et Biologique 1991; 15: A158).

7 Page6 BEAUGERIE L, GOUJARD F, GHARAKHANIAN S, MALAFOSSE M, LE QUINTREC Y, ROZENBAUM W. Etiology and management of toxic megacolon in AIDS patients. VII International Conference on AIDS, Florence, June 1991 (Abstract MB 2204). COSNES J, GHARAKHANIAN S, BEAUGERIE L, LAMY PH, GENDRE JP, LE QUINTREC Y, ROZENBAUM W. Enteral nutrition in AIDS : results in patients with digestive disease. VII International Conference on AIDS, Florence, June 1991 (Abstract MB 2241). CHRISTEFF N, GHARAKHANIAN S, DADOUN C, THOBIE N, ROZENBAUM W, NUNEZ EA. Lipid variations in different stages of HIV infection. VII International Conference on AIDS, Florence, June 1991 (Abstract WB 2138). ROZENBAUM W, DIAS TAVARES M, NAVARETTE MS, GHARAKHANIAN S, CARDON B, LEBRETTE MG. Evaluation of Trimethoprim-Sulfamethoxazole vs aerosolized Pentamidine, with concomitant onset of Zidovudine in Primary Pneumocystis carinii pneumonia prophylaxis. VII International Conference on AIDS, Florence, June 1991 (abstract 2247). ROZENBAUM W, TABAH I, GHARAKHANIAN S, CARDON B, BIDEAULT H. Randomized study of 3 different dosages of Interferon alpha 2B for well-responding AIDSrelated Kaposis sarcoma. VII International Conference on AIDS, Florence, June 1991 (abstract 2374). TRYSLINSKI A, FEUILLADE M, BENKHRABA F, GHARAKHANIAN S, CARBONNEL F, DELUOL AM, ROUJEAU JC. Histoplasmose disséminée diagnostiquée è partir des lésions cutanées chez un patient VIH+ ayant séjourné 18 ans auparavant en Colombie. Société Française de Mycologie Médicale, Tours, May 1991 (abstract ). DAB DH, LINARD F, SILVESTRE D, ROZENBAUM W, GHARAKHANIAN S, DIAS TAVARES M. Announcing positive results of HIV serology and related ethical problems. International Conference on Biopsychosocial aspects of HIV infection, Amsterdam, September 1991 (abstract ). GOUNY P, GIRARD PM, CHATLET F, DENEUVILLE M, GHARAKHANIAN S, ROZENBAUM W, NAUSSAUME O. Mycobacterium Tuberculosis infected abdominal aortic aneurysm in a HIV patient.3rd European conference on clinical aspects and treatment of HIV infection, Paris, March 1992 (abstract 060).

8 Page7 GHARAKHANIAN S, LAMY PH, LUBOINSKI J, GOETSCHEL A, GENDRE JP, ROZENBAUM W. Gastrointestinal malacoplakia in a patient with AIDS. 3rd European conference on clinical aspects and treatment of HIV infection, Paris, March 1992 (abstract 305). GIRARD PM, MILKA-CABANNE N, VOLPELLIER N, LEBRETTE MG, GHARAKHANIAN S, ROZENBAUM W. Influence of general recommendations for primary prophylaxis of features of Pneumocystis carinii pneumonia in HIV-infected patients. Réunion interdisciplinaire de chimiothérapie anti-infectieuse (RICAI), Paris, December 1992 (abstract: theme 15). CHRISTEFF N, GHARAKHANIAN S, THOBIE N, WIRBEL E, ROZENBAUM W. Effect of Interferon 2A on serum androgen in HIV + men with Kaposi s sarcoma. Xth International Conference on AIDS, Yokohama, August 1994 (abstract 2758) GHARAKHANIAN S, ROZENBAUM W. Treatment of HIV-related neutropenia : problems and perspectives. Round table meeting at the 1 st International Symposium on Cytokines & HIV disease, Reims, March In Haematopoietic Growth Factors & the treatment of HIV Diseases. GAZZARD BG (editor). London : Mediscript, 1995 : CHRISTEFF, N, GHARAKHANIAN S, WINTER C, COSTAGLIOLA D, NUNEZ E, ROZENBAUM W. Concéntrations sériques des androgènes au cours de la maladie de Kaposi associé à l infection VIH 1 ère Forum Francophone Maladie de Kaposi - Infection VIH, Lyon, May 1996.(Nouvelles Dermatologiques 1996;15 (suppl 1) : 26-32) CHRISTEFF N, GHERBI N, MAMMES O, GHARAKHANIAN S, ORTHOLARY O, MELCHIOR JC, NUNEZ E. Serum cortisol and DHEA concentrations during HIV infection. 1 st International Conference on Cortisol & Anticortisols, Fillerval, June 1996 (abstract ). SAPSE AT, CHRISTEFF N, GHARAKHANIAN S, GHERBI N, NUNEZ E. A new 24-hour circadian rhythm chart questions the validity of present reporting of cortisol values in health and diseases. 2nd International Conference on Cortisol & Anticortisols, Las Vegas, November 1997 (abstract p 51).

9 Page8 GHARAKHANIAN S, DUBREUIL-LEMAIRE ML, GORI A, VITTECOQ D, PANELATTI G, THARAUX F, ROZENBAUM W. A multicentre, European, randomised, single-blind, phase IIa study of lenograstim (rhug-csf) to allow optimal ganciclovir treatment of CMV infection in neutropenic AIDS patients.. XIIth World AIDS Conference, Geneva, July 1998 (abstract 32146). GHARAKHANIAN S, MORGENSZTEIN N, GUESSANT-FLAMBARD S, MASLO C, MENGIBETO A, PIHOUEE PH, ROZENBAUM W. Utilisation of colony stimulating factors (CSF) in an HIV treatment centre : CSF initiation modalities and impact on anti-infective agent use. XIIth World AIDS Conference, Geneva, July 1998 (abstract 42436). GHARAKHANIAN S. Lipodystrophies liées aux therapeutiques antiretrovirales. 11 ème Colloque du Centre -Etablissements de Traitement et de Recherche Anti-SIDA (CITRAS), AP- HP. Paris, November GHARAKHANIAN S, SALHI Y, NGUYEN TH-H, ADDA N, VIGOUROUX C, CAPEAU J, ROZENBAUM W. Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated by protease inhibitors. 6 th Conference on Retroviruses & Opportunistic Infections, Chicago, Feb 1999 (abstract 642) VIGOUROUX C, GHARAKHANIAN S, SALHI Y, NGUYEN TY, ADDA N, CATRIX S, CAPEAU J, ROZENBAUM W. Fréquance du syndrome lipodystrophique et des altération de la tolérance au glucose chez 192 patients VIH+ traités par antiprotease. ALFEDIAM, Paris, April 1999, (Diabète et Métabolisme, abstract O23). VIGOUROUX C, GHARAKHANIAN S, SALHI Y, NGUYEN TY, ADDA N, CAPEAU J, ROZENBAUM W. Occurance of lipodystrophy, altered glucose tolerance, insuline rsistance and dyslipidemia in 192 HIV+ patients treated with protease inhibitors. 59 th Scientific Session of the American Diabetes Association (ADA), San Diego, June 1999, (Diabetes, abstract 349). ROZENBAUM W, GHARAKHANIAN S, SALHI Y, ADDA N, NGUYEN TY, VIGOUROUX C, CAPEAU J.. Clinical and laboratory characteristics of lipodystrophy in a French cohort of HIV-infected patients treated with protease-inhibitors 1 st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, June Antiviral Therapy, abstract 012.

10 Page9 ROZENBAUM W, NGUYEN TY, SALHI Y, ADDA N, VIGOUROUX C, CAPEAU J.. GHARAKHANIAN S. Prospective follow-up of a protease inhibitor substitution for efavirenz in patients with the HIVassociated lipodystrophy syndrome (HALS) 1 st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, June Antiviral Therapy, abstract 068. GHARAKHANIAN S., SALHI Y, ADDA N, VIGOUROUX C, CAPEAU J., ROZENBAUM W, Evaluation des caractéristiques cliniques et biologiques de la lipodystrophie liée au VIH dans une cohorte de patients traités par deux analogues nucléosidiques et un inhibiteur de protéase. 3 ème Séminaire Annuel de Recherche Clinique sur l Infection par le VIH de l ANRS, Paris, December 1999, (abstract 09) GHARAKHANIAN S., SALHI Y, ADDA N, VIGOUROUX C, CAPEAU J., ROZENBAUM W. Identification of fat redistribution/metabolic abnormalities in a cohort treated by 2 NRTIs and 1 PI, and absence of significant modification following PI substitution. 7 th Conference on Retroviruses & Opportunistic Infections, Chicago, Jan-Feb 2000 (abstract 46) ADDA N, SALHI Y, GHARAKHANIAN S, ROZENBAUM W. Evolution of clinical and laboratory features, in patients with the HIV-associated lipodystrophy syndrome, treated by HAART regimens including amprenavir. 2 nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, September Antiviral Therapy, abstract 061. SLAMA L, CHESNEY M, ROZENBAUM W, GHARAKHANIAN S Conception et réalisation d un outil d aide à l observance des traitements de l infection par le VIH 1er Congrès National sur l Observence Thérapeutique (FNCLS), Nantes, October 2000.(abstract A31). AUBERT JP, BIDEAULT H, COMPAGNON C, COSTAGLIOLA D, ELGOZI B, GHARAKHANIAN S, JACQUEMIN C, LEBBADI M, LIVROZET JM, MAMET JP, PREVOTEAU F, SOUFFLET A, THIAUX C, WAJBROT A. MILO : conception et réalisation par les généralistes des reseaux Ville-Hôpital d un essai clinique dans l infection par le VIH. 2ème Congrès de Recherche en Médecine Générale, Biarritz, 31 March-01 April 2001.

11 Page10 BYRN RA, GHARAKHANIAN S. Abacavir shows potent synergistic anti-hiv activity with amprenavir but fails to show synergy with Inosine Monophosphate Dehydrogenase (IMPDH) inhibitors, in vivo. XI Symposium on HIV infection, June 2001, Toulouse (Abstract E-25). GHARAKHANIAN S. From drug discovery to therapeutic drug monitoring (TDM) in HIV infection. XI Symposium on HIV infection, June 2001, Toulouse (Abstract SS.7.1). TUNG R, SPALTENSTEIN A, MILLARD J, GHARAKHANIAN S., POTTAGE S, YEO J, FURFINE E. Characterisation of GW908/VX175, a new protease inhibitor evaluated in various clinical settings. 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATH), October 2001, Athens (Abstract p 31) GHARAKHANIAN S., LENHARD J, WIEIL J, POTTAGE S, FURFINE E Lipodystrophy & metabolic profile of a PI : evaluation of amprenavir via in vitro, animal and human studies. 8th European Conference on Clinical Aspects and Treatment of HIV Infection (ECCATH), October 2001, Athens (Abstract 107) ADDA N, GHARAKHANIAN S, SALHI Y, ROZENBAUM W. Evaluation rétrospective, clinique et biologique, chez des patients avec une lipodystrophie, traités pas amprenavir. IIeme Congres Nationale, FNCLS, October 2001, Montpellier, abstract A9. Amiel C; Slama L; NGuyen T; Nai-Ighil L; Gharakhanian S; Rozenbaum W; de Vernejoul M C; Ostertag, A, Lajeunie, E. Osteoporosis and osteopenia in treatd and not treated HIVpositive patients. 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV Athens, Greece. BAKER CT, CHATURVEDI P, HALE MR, FURFINE E, SPALTENSTEIN A, GHARAKHANIAN S, Tung RD. Mise au point et caractérisation d un nouvel inhibiteur de protéase du VIH : le GW908/VX175. Journées Nationales d Infectiologie, June 2002, Grenoble, abstract P076. GARG V, BRILL M, BEELER L, KHANLOU H, GATHE J, GHARAKHANIAN S Intéractions amprenavir/lopinavir : résultats d etudes et revue de la littérature. Journées Nationales d Infectiologie, June 2002, Grenoble, abstract P075.

12 Page11 VIGOUROUX C, MAACHI M, NGUYEN TH-H, SALHI Y, COUSSIEU S, GHARAKHANIAN S, FUNHASHI T, MATSUZAWA Y, SHIMOMURA I, ROZENBAUM W, CAPEAU J, BASTARD J-P. Adiponectine, leptine and soluble TNF receptors circulating levels are related to insuline resistance and cardiovascular risk factors in HIV patients under antiretroviral therapy. 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, September Antiviral Therapy, 2002;7 :L24, abstract 34. JAYAWEERA D, TANNER, T, BRILL M, CAMPO R, RODRIGUEZ A, KOLBERT M, GHARAKHANIAN S. Evaluation de la méthode «traitement directement observé (TDO)» au cours de l infection VIH : résultats à 48 semaines après 24 semaines de TDO. Journées Nationales d Infectiologie, June 2003, Lille, abstract A29 GATTI G, DE PASCALIS CR, DE LUCA A, DI BIAGIO A, ZUCCHI P, MASERATI R, TRENTINI L, BONORA S, MERAVIGLIA P, GHARAKHANIAN S, BASSETTI D. Les inter-relations entre les résultats virologiques et immunologiques chez des patients multiprétraités des antiretroviraux et remis sous amprénavir. Journées Nationales d Infectiologie, June 2003, Lille, abstract A30 LE CAMUS S, ANTOUN Z, GHARAKHANIAN S. Galénique des inhibiteurs de protéase et éfficacité au long terme du traitement du VIH : à propos du Fosamprenavir. Vème Congrès de la Société Française de Lutte contre le SIDA (SFLS), October 2004, Tours, Poster 15. LUBER A, GARG G, GHARAKHAIAN S. Survey of medication used by HIV Infected patients that affect gastrointestinal acidity and potenial for negative drug interactions withy HAART. 7 th International Congress on Drug Therapy in HIV Infection, November 2004, Glasgow, Poster 206.

13 Page GHARAKHANIAN S, KHANLOU H, LE CAMUS C, FARTHING C Interaction entre fosamrenavir et atrazanavir avec ou sans ritonavir dans le traitement des patients infectes par le VIH; résultants préliminaires en pratique clinique courante. Journées Nationales d Infectiologie, 8-10 June 2005, Nice, abstract COL 9-01 LUBER A, GHARAKHANIAN S. Interactions entre médicaments modifiant l acidité gastrique et inhibiteurs de protéase chez des patients infectées par le VIH.. Journées Nationales d Infectiologie, 8-10 June 2005, Nice, abstract E18. RAFFI F, ANTOUN Z, LE CAMUS C, HADACEK B, GHARAKHANIAN S Pharmacokinetic results (PK) following dosage modulation of fosamprenavir (FPV) with ritonavir (RTV). 10 th European AIDS Clinical Society Conference, November 2005, Dublin. Poster PE 4.2/3 GHARAKHANIAN S, GARTLAND MJ, YEO JM Lipodystrophy & metabolic profile of an HIV Protease Inhibitor (PI): evaluation of Fosamprenavir via In Vitro and Human Studies. 10 th European AIDS Clinical Society Conference, November 2005, Dublin Poster PE 9.3/3 POIRIER JM, MICHELON H, LESCURE X, MEYNARD JL, GUIRARD-SCMID JB, GHARAKHANIAN S, BONNARD P, ZOUAI O, JAILLON P, PIALOUX G, GIRARD PM. Lack of effect of gender, race, age, weigh and body mass index on trough amprenavir plasma concentrations in HIV-infected patients with ritonavir boosted fosamprenavir. 7 th International Workshop on Clinical Pharmacology of HIV Therapy, April 2006, Lisbon, Poster 7. MICHELON H, POIRIER JM, LESCURE X, MEYNARD JL, GUIRARD-SCMID JB, GHARAKHANIAN S, BONNARD P, ZOUAI O, JAILLON P, PIALOUX G, GIRARD PM. Absence de l effet de l âge, du sexe, du poids, de l index de masse corporelle et de l origine ethnique sur la concentration résiduelle de l amprenavir chez les patients traites par fosamprenavir boosté. Journées Nationales d Infectiologie, 8-9 June 2006, Bordeaux, abstract G-30. ACOSTA EP, PARKS D, PEYTAVIN G, LE CAMUS C, GHARAKHANIAN S. L association Fosamprenavir et Tenofovir disoproxil fumarate chez les patients infectees par le VIH : donnees pharmacologiaques, virologiques et cliniques. Journées Nationales d Infectiologie, 8-9 June 2006, Bordeaux, abstract G-32.

14 Page13 LE CAMUS C, HADACEK B, ANTOUN Z, GHARAKHANIAN S. Revue systématique des données de tolérance hépatique du Fosamprenavir chez les patients connectées VIH/Hépatites Virales. Journées Nationales d Infectiologie, 8-9 June 2006, Bordeaux, abstract G-34. HEZODE C, FERENCI P, DUSHEIKO G, POL S, GOESER TH, BRONOWICKI JP, GHARAKHANIAN S, DESIREE DEVONISH D, ROBERT KAUFFMAN R, ALAM J, PAWLOTSKY J-P, STEFAN ZEUZEM S 9 & THE PROVE2 STUDY TEAM. PROVE2: phase II study of VX950 (telaprevir) in combination with Peginterferon alfa2a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis. 58 th Amercican Association Study of Lver Disease [AASLD), 2-6 November 2007, Boston. Hepatology 2007, 46 (Suppl), 80: 268A. FERENCI P, PAWLOTSKY JM, ZEUZEM S, DUSHEIKO G, BOURLIÈRE M, BUGGISCH P,, SERFATY L, LEIF BENGTSSON L, GHARAKHANIAN S, KAUFFMAN R, ALAM J, & THE PROVE2 STUDY TEAM. Telaprevir (VX950, TVR) combination with Peginterferon alfa2a (PEG-IFN), with or without ribavirin (RBV), in treatment of subjects with chronic Genotype 1 (G1) hepatitis C (HCV). A Planned interim analysis (IA) of Study VX EU PROVE2.Asia-Pacific Association for the Study of Liver Disease Conference [APASL], Seoul, 2008 [abstract ] DUSHEIKO GM, HÉZODE C, POL S, GOESER T, BRONOWICKI J-P, BOURLIERE M,BUGGISCH P, SERFATY L, BERG T, COUZIGOU P, BENHAMOU Y, FORESTIER N, BENGTSSON L, GHARAKHANIAN S, KAUFFMAN R, ALAM J, FERENCI PAWLOTSKY J-M, ZEUZEM S, ON BEHALF OF THE PROVE2 STUDY TEAM (FRANCE, GERMANY, AUSTRIA, USA, UK) Treatment of Chronic Hepatitis C with Telaprevir in Combination with Peginterferon Alfa-2a with or without Ribavirin: Interim Results of the PROVE2 Study 43 rd European Association Study of Liver Disease[EASL], 23-7 April, Milan, J Hepatology 2008;48 (Suppl 2), 58, S26. HEZODE C, FERENCI P, DUSHEIKO G, TRAN A, GRANGÉ J-D, MATHURIN PH, SCHMIDT W, DIEPOLDER H, MARCELLIN P, WEDEMEYER H, FORESTIER N, MANGELS W, GHARAKHANIAN S, KAUFFMAN R, ALAM J, PAWLOTSKY J-M, ZEUZEM S. PROVE2 Study: Treatment of chronic hepatitis C with telaprevir (TVR) in combination with Peginterferon-alfa-2a with or without ribavirin, Interim Analysis Results. Digestive Diseases Week Conference (DDW), 2008, San Diego. Gastroenterology, Volume 134, Issue 4, Supplement 1, April 2008, Pages A-755 HÉZODE C, POL S, BRONOWICKI J-P, BOURLIÈRE M, SERFATY L, COUZIGOU P, MATHURIN P, TRAN A, BENHAMOU Y, MARCELLIN P, GRANGE JD, TREPO C, ZARSKI JP, DEVONISH D, GHARAKHANIAN S, KAUFFMAN R, PAWLOTSKY JM POUR L EQUIPE DE PROVE2. Résultats intérimaires de l étude PROVE2, essai de phase 2 associant Telaprevir, un inhibiteur spécifique de la protéase NS3 du VHC, à l interféron alfa-2a pegylé avec ou sans ribavirine. Association Française de l Etude du Foie AFEF], Paris, September 24-27, Gastroentrologie Clinique et Biologique 2008 ;32 :CO-45, p 49.

15 Page SULKOWSKI M, DIETRICH D, SHERMAN K, ROCKSTROH J, ADDA N, MAHNKE L GARG V, GHARAKHANIAN S, MACALLISTER S, SORIANO V. Interim analysis of a phase 2a double-blind study of TVR in combination with PEGIFN-a2a and RBV in HIV/HCV co-infected patients. 18 th Conference on Retroviruses and Opportunistic Infections (CROI); Boston MA, Feb.27-Mar.2, 2011; abstract 146LB. DIETERICH DD, JÜRGEN K ROCKSTROH JK, SHERMAN KE, ADDA N, MAHNKE L, GARG V, GHARAKHANIAN S, MCCALLISTER S, SORIANO V, SULKOWSKI M Interim Analysis of a Phase 2a Double-Blind Study of Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin in HIV/HCV-Coinfected Patients. International Conference on Viral Hepatitis, Baltimore MD, April 11-12, 2011, Abstract NAGRAJ M, ANDRZEJ ARDZINSKI A, LUONG Y-P, DE MEYER S2, GHYS A, LIN T-I, PICCHIO G, RA G,TAYLOR W, GHARAKHANIAN S, KWONG AD. In Vitro Selectivity Studies Comparing HCV Protease Inhibitor Telaprevir and HIV Protease and Reverse Transcriptase Inhibitors. International Conference on Viral Hepatitis, Baltimore MD, April 11-12, 2011, Abstract GHARAKHANIAN S. Role of Medical Affairs in Medical Education. Medical Affairs Executive Forum, April 2011, Basking Ridge NJ. https://exlpharma.boxenterprise.net/medical affairsforum. SORIANO, V, SHERMAN, K.E, ROCKSTROH, J.K, DIETERICH, D.T.; ADDA, N, MAHNKE, L, GARG,V, GHARAKHANIAN, S, MCCALLISTER, S, SULKOWSKI, MS. Interim analysis of phase 2a bouble blind study of telaprevir in combination with peginterferon alpha-2a and ribavirin in HIV/HCV coinfected patients. 7 th International Workshop on HV and Hepatitis coinfection. 1-3 June 2011 Milan, Italy GHARAKHANIAN S. Challenge of clinical development of anti-infective drugs Keynote lecture. French Biotech Tour Meeting. International Partnerships in Diagnostics and Therapeutics. UBIFRANCE United States. US French Embassy Trade Office. 11 September 2011, MIT Faculty Club, Boston MA. GHARAKHANIAN S. Valuable role of medical affairs in new drug approval and launch Medical Affairs Executive Forum, April 2012, Morristown NJ. https://exlpharma.boxenterprise.net/medical affairsforum.

16 Page15 CROUZET J, VIEILLARD V, DEBRE P, KATLAMA C, LAUNAY O, HO TSONG FANG R, DESFONTAINES- BATÉJAT D, MARCU M, GHARAKHANIAN S. Potential role of anti-3s antibodies in an HIV medical cure strategy? Workshop on HIV Cure and Eradication. Milan, Italy, January, KATLAMA C, LAUNAY O, HO TSONG FANG R, BODILIS H, CALIN R, AUTRAN B, GHARAKHANIAN S, VIEILLARD V, CROUZET J, DEBRE P. A randomized, placebo-controlled, double-blind, phase I/I dose escalation study of an HIV immunotherapeutic vaccine, VAC-3S, directed to the gp41 3S motif of HIV-1. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, Georgia, 3-6March, Abstract#392 GHARAKHANIAN S. Precision Medicine / Personnalized Medicine & HIV Infection: concepts & applications? [Invited Lecture] Annual Research Seminar of the French National HIV & Hepatitis Agency. Seminaire de Recherche ANRS Apil [abstract & summary KATLAMA C LAUNAY O, GHARAKHANIAM S, HI TSONG FANG R, AUTRAN B, VIELLARD V, COUZET MURPHY R, DEBRE P. Experimental evidence and potential immunotherapeutic applications of vaccine-induced antibodies against 3S, a highly conserved motif of gp41, in HIV-1 infected patients treated with antiretroviral therapy. 30 Years of HIV Science symposium. Institut Pasteur, Paris France, 21-23May, Poster # 145. CALIN R, BODILIS H, HO TSONG FANG R, LAUNEY O, KATLAMA K, GHARAKHANIAN S. Etude de phase I/IIa de VAC-3S: une vaccine immune thérapeutique/immunoprotecteur, en complément des antirétroviraux, au cours de l infection VIH. Journées Nationales d Infectiologie, Cl Ferrand France, Juin Poster

17 Page16 PUBLICATIONS < MOZAFFARIAN G, KAMAL D, GHARAKHANIAN S, SABERI X. Trace elements and diabetes mellitus Behkosh Medical Journal 1979;3 : ROZENBAUM W, GHARAKHANIAN S. Aspects cliniques de l infection par le virus LAV/HTLV III. Concours Médical 1986; 108 : POLLAK M, ROZENBAUM W, VIALLEFOND A, GHARAKHANIAN S, AIME F. Les conséquences psychosociales de l infection HIV. Revue d Epidémiologie et de Santé Publique 1988; 36 : ROZENBAUM W, GHARAKHANIAN S, CARDON B, DUVAL E, COULAUD JP. HIV transmission by oral sex. Lancet 1988; 1: ROZENBAUM W, GHARAKHANIAN S, CARDON B, DUVAL E, COULAUD JP. HIV and orogenital transmission. Lancet 1988; 2: DOURNON E, MATHERON S, ROZENBAUM W, GHARAKHANIAN S, MICHON C, GIRARD PM, PERRONNE C, SALMON D, DE TRUCHIS P, LEPORT C, BOUVET E, DAZZA MC, LEVACHER M, REGNIER B, AND THE CLAUDE BERNARD HOSPITAL AZT STUDY GROUP. Effects of Zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 1988; 2 : BOURNERIAS I, BOISNIC S, PATEY O, DENY P, GHARAKHANIAN S, DUFLO B, GENTILINI M. Unusual cutaneous cytomegalovirus involvement in AIDS patients. Archives of Dermatology 1989; 125:

18 Page CNUDDE F, CHAUVIN P, GHARAKHANIAN S, LEYNADIER F, ROZENBAUM W, DRY J. L allergie immédiate médicamenteuse chez les malades immunodéprimés. Presse Médicale 1990; 30 : GHARAKHANIAN S, NAVARETTE MS, CARDON B, ROZENBAUM W. Vitamine B12 injections in patients treated with Zidovudine. AIDS 1990; 4: ROZENBAUM W, GHARAKHANIAN S, NAVARETTE MS, DE SAHB R, CARDON B. Long-term follow-up 120 patients with AIDS-related Kaposi s Sarcoma treated with Interferon alpha-2a. Journal of Investigational Dermatology 1990; 95: 161S-165S. CNUDDE F, GHARAKHANIANIAN S, LUBOINSKI J, DRY J, ROZENBAUM W. Cutaneous local necrosis following Interferon injections. International Journal of Dermatology 1991; 30: 147. BEAUGERIE L, GOUJARD F, DESLANDES M, GHARAKHANIAN S, LAMY PH, COSNES J, GENDRE JP, LE QUINTRE Y, ROZENBAUM W, MALAFOSSE M. Toxic megacolon in AIDS patients. Gastroenterology 1991; 100: A560. GABARRE J, AZAR N, OTHMAN TB, GHARAKHANIAN S, DE SAHB R, DOHIN E, SANSONETTI P, LANGLOIS P, ECHARD M, GLATFOSSE M, BINET JL. Effects à long terme de la splénectomie pour purpura thrombopénique immunologique dû au VIH. Presse Médicale 1991; 20: COCHEREAU-MASSIN I, LEHOANG P, ROBINET M, MATHERON S, KATLAMA C, GHARAKHANIAN S, ROZENBAUM W, INGRAND D, GENTILINI M. Efficacy and tolerance of intravitreal ganciclovir in CMV retinitis in AIDS. Ophthalmology 1991; 98: COSNES J, BEAUGERIE L, LAMY P, GHARAKHANIAN S, BELLANGER J, GENDRE JP, LE QUINTREC Y. Nutrition entérale dans le SIDA compliqué d attiente digestive Nutrition Clinique Métabol. 1991;5 : CHRISTEFF N, GHARAKHANIAN S, THOBIE N, ROZENBAUM W, NUNEZ E. Evidence for changes in adrenal and testicular steroids during HIV infection Journal of the Acquired Immune Deficiency Syndrom 1992;5:

19 Page18 BEAUGERIE L, NGO Y, GOUJARD F, GHARAKHANIAN S, CARBONNEL F, LUBOINSKI J, MALAFOSSE H, ROZENBAUM W, LE QUINTREC Y. Etiology and management of toxic megacolon in HIV infected patients. Gastroenterology 1994;107: CHRISTEFF N, WINTER C, GHARAKHANIAN S, THOBIE N, WIRBEL E, COSTAGLIOLA D, NUNEZ EA, ROZENBAUM W. Differences in androgens of HIV positive patients with and without Kaposi s sarcoma. Journal of Clinical Pathology 1995; 48: TRYSLINSKI A, CARBONNEL F, BOUCHAUD O, BEAUGERIE L, GHARAKHANIAN S, ROZENBAUM W, COSNES J, GENDRE JP, LE QUINTREC Y. Intestinal histoplasmosis in AIDS patients : report of three cases observed in France and review of the literature. European Journal of Gastroenterology & Hepatology 1995; 7 : CHRISTEFF N, GHARAKHANIAN S, THOBIE N, WIRBEL E, DALLE MT, COSTAGLIOLA D, NUNEZ EA, ROZENBAUM W. Effect of interferon on high serum androgen concentrations in HIV positive men with and without Kaposi s sarcoma. Journal of Clinical Pathology 1997; 50: CHRISTEFF N, GHERBI N, MAMMES O, DALLE MT, GHARAKHANIAN S, LORTHOLARY O ET AL. Serum cortisol & DHEA concentrations during HIV infection. Psychoneuroendocrinology 1997; S11-8. VIGOUROUX C, GHARAKHANIAN S, SALHI Y, NGUYEN TY, ADDA N, ROZENBAUM W, CAPEAU J. Les anomalies métaboliques secondaires aux traitements antiviraux de l infection par le VIH. Cahiers de Nutrition et Dietétique 1999, 34 : VIGOUROUX C, GHARAKHANIAN S, SALHI Y, NGUYEN TY, CHEVENNE D, CAPEAU J, ROZENBAUM W. Diabetes, insulin resistance and dyslipidemia in lipodystrophic HIV-infected patients on Highly Active Antiretroviral Therapy (HAART) Diabetes & Metabolism (Paris) 1999, 25 ; VIGOUROUX C, GHARAKHANIAN S, SALHI Y, NGUYEN TY, ROZENBAUM W., CAPEAU J. Adverse metabolic disorders during Highly Active Antiretroviral Treatments (HAART) of HIV disease. Diabetes & Metabolism (Paris) 1999, 25 :

20 Page DUBREUIL-LEMAIRE M-L, GORI A, SALHI Y, VITTECOQ D, PANELATTI G, THARAUX F, PALISSES R, GHARAKHANIAN S, ROZENBAUM W. Lenograstim for the.treatment of neutropenia in patients with CMV infection receiving ganciclovir : a randomised, placebo-controlled trial. European Journal of Haematology, 2000 ;65 : DUARTE C, BAEHRE M, GHARAKHANIAN S, LEYNADIER F & THE FRENCH AZELASTINE GROUP. Treatment of severe seasonal rhino-conjonctivities by a combination of azelastine spray and eye drops : a double-blind, double-placebo study. J of Investigational Allergology & Clinical Immunology 2001 ; 11 : GHARAKHANIAN S. The HIV-associated lipodystrophy syndrome : research, results, yet more questions [Editorial Comment] AIDS 2001 ; 15 : VIGOUROUX C, MAACHI M, NGUYEN TH-H, SALHI Y, COUSSIEU S, GHARAKHANIAN S, FUNHASHI T, MATSUZAWA Y, SHIMOMURA I, ROZENBAUM W, CAPEAU J, BASTARD J-P. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003; 17: GHARAKHANIAN, S. Traitement du VHC: peut-on faire court (12 semaines). Transcriptase 2005 ; 124 : GHARAKHANIAN S, BOCCARA F, CAPEAU J. Statins in HIV associated lipodystrophy and metabolic syndrome: Is there a missing link? [Editorial Comment] AIDS 2006; 20:

Hepatitis C Glossary of Terms

Hepatitis C Glossary of Terms Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune

More information

Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total

Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n

More information

Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA

Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive

More information

Acute HCV was defined as (3 out of 4 within the preceding 4 months):

Acute HCV was defined as (3 out of 4 within the preceding 4 months): Christoph Boesecke, Patrick Ingiliz, Hans-Jürgen Stellbrink, Mark Nelson, Sanjay Bhagani, Marguerite Guiguet, Marc-Antoine Valantin, Thomas Reiberger, Martin Vogel, Jürgen K. Rockstroh, and the NEAT study

More information

Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?

Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence

More information

Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012

Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012 Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public

More information

HIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations

HIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic

More information

HIV/Hepatitis C co-infection. Update on treatment Eoin Feeney

HIV/Hepatitis C co-infection. Update on treatment Eoin Feeney HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What

More information

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)

More information

Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients

Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of

More information

Hepatitis C Treatment of Active IV Drug Users Tania Dunn, RN Isabelle Gendron, RN B.Sc.

Hepatitis C Treatment of Active IV Drug Users Tania Dunn, RN Isabelle Gendron, RN B.Sc. Hepatitis C Treatment of Active IV Drug Users Tania Dunn, RN Isabelle Gendron, RN B.Sc. CRD Le Virage Équipe TDO GMF de l UMF Charles LeMoyne St-Lambert, Quebec February 2012 Potential Conflicts of Interest

More information

Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing

Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing ANRS -COPHAR clinical trial Céline Verstuyft Pharmacologie,

More information

Antiretroviral therapy for HIV infection in infants and children: Towards universal access

Antiretroviral therapy for HIV infection in infants and children: Towards universal access Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous

More information

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf

More information

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052)

Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C. Daclatasvir (Daklinza, DCV, BMS-790052) Antiretroviral Treatment Options for Patients on Directly Acting Antivirals for Hepatitis C PIs: atazanavir PIs: other Simeprevir with ritonavir- or cobicistat boosted PIs (significant simeprevir AUC).

More information

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections

Chapter 36. Media Directory. Characteristics of Viruses. Primitive Structure of Viruses. Therapy for Viral Infections. Drugs for Viral Infections Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.

More information

Ribavirin/Pegylated Interferon Combination Therapy for People with Hepatitis C

Ribavirin/Pegylated Interferon Combination Therapy for People with Hepatitis C Ribavirin/Pegylated Combination Therapy for People with Hepatitis C 1. Introduction 2. What the treatment does 3. When to take it 4. What is? 5. What is interferon? 6. What is pegylated interferon? 7.

More information

in HIV/HCV-Coinfected Patients: role of the HCV sustained viral suppression

in HIV/HCV-Coinfected Patients: role of the HCV sustained viral suppression M42-Determinants M19 of HIV Sustained Viral Suppression in HIV/HCV-Coinfected Patients: role of the HCV sustained viral suppression F. Bani-Sadr 1-2, M-A Loko 2, E. Pambrun 2, M. Winnock 2, P. Carrieri

More information

Innovazione farmacologica e farmacologia clinica

Innovazione farmacologica e farmacologia clinica Innovazione farmacologica e farmacologia clinica Francesco Scaglione, MD, PhD Department of Medical Biotechnology and Translational Medicine School of medicine Postgradute School of clinical pharmacology

More information

HEPATITIS COINFECTIONS

HEPATITIS COINFECTIONS HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)

More information

L hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015

L hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015 L hépatite virale C en Médecine Familiale- Rurale Montréal-Québec Mai 2015 Demographics Luis Rivero Pinelo MD LMCC, CCFP, FCFP, Fellow SRPC, CSPQ Shawville- Québec Aux États Unis, la prévalence est présente

More information

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical

More information

Noam Danenberg CEO N. Danenberg Holding Ltd noam@danenberg.co.il

Noam Danenberg CEO N. Danenberg Holding Ltd noam@danenberg.co.il Noam Danenberg CEO N. Danenberg Holding Ltd noam@danenberg.co.il Experience CEO at N. Danenberg Holding (2000) Ltd) 2000 - Present (13 years) Investment Consulting Firm Consultant at Bonzai Holding Ltd.

More information

CIBMTR Infection Data and the New Infection Inserts.

CIBMTR Infection Data and the New Infection Inserts. CIBMTR Infection Data and the New Infection Inserts. Marcie Tomblyn, MD, MS Scientific Director, CIBMTR Infection and Immune Reconstitution Working Committee Overview Indication for expanded data collection

More information

Victrelis: hints for success. Katarnya Gilbert Hepatology MSL MSD

Victrelis: hints for success. Katarnya Gilbert Hepatology MSL MSD Victrelis: hints for success Katarnya Gilbert Hepatology MSL MSD 1 Some Facts: BOC has no clinically significant activity against other HCV genotypes. Resistance with protease inhibitor monotherapy can

More information

Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* Overview. To change category names: Instructions. 2. Introduce session.

Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* Overview. To change category names: Instructions. 2. Introduce session. Core Competencies: HIV/AIDS: HIV Basics HIV/AIDS JEOPARDY* ABOUT THIS ACTIVITY Time: 60 minutes Objectives: By the end of this session, participants will be able to: Reviewed their knowledge of HIV/AIDS

More information

HIV/AIDS Care: The Diagnosis Code Series 2. Prepared By: Stacey L. Murphy, MPA, RHIA, CPC AHIMA Approved ICD-10-CM/ICD-10-CM Trainer

HIV/AIDS Care: The Diagnosis Code Series 2. Prepared By: Stacey L. Murphy, MPA, RHIA, CPC AHIMA Approved ICD-10-CM/ICD-10-CM Trainer HIV/AIDS Care: The Diagnosis Code Series 2 Prepared By: Stacey L. Murphy, MPA, RHIA, CPC AHIMA Approved ICD-10-CM/ICD-10-CM Trainer Learning Outcomes Identify and explain the difference between ICD-9-CM

More information

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000

More information

Perspective Advances in the Treatment of Hepatitis C Virus Infection

Perspective Advances in the Treatment of Hepatitis C Virus Infection Advances in HCV Treatment Volume 20 Issue 1 April/May 2012 Perspective Advances in the Treatment of Hepatitis C Virus Infection Since 2007, the annual age-adjusted mortality rate in hepatitis C virus (HCV)

More information

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd

boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium peginterferon alfa-2a, 135 microgram/ml and 180 microgram/ml pre-filled injections of solution for subcutaneous injection (Pegasys ) No. (561/09) Roche Products Limited 10

More information

THE VIRAL HEPATITIS CONGRESS 2015. 10 12 September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme

THE VIRAL HEPATITIS CONGRESS 2015. 10 12 September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme THE VIRAL HEPATITIS CONGRESS THE VIRAL HEPATITIS CONGRESS 2015 10 12 September 2015, Kap Europa, Frankfurt, Germany Scientific Programme PRE-CONGRESS WORKSHOP SPONSOR ACHILLION Achillion is seeking to

More information

Post AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in

Post AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze Will predictors usefull

More information

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

More information

LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova

LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune

More information

Chapter 10 Human Immuno Deficiency Virus Infection

Chapter 10 Human Immuno Deficiency Virus Infection 143 Chapter 10 Human Immuno Deficiency Virus Infection Chapter 10 Human Immuno Deficiency Virus Infection...143 HIV infection...144 Clinical Features...146 Clinical Staging of HIV infection recommended

More information

Current Opinion in Hepatitis C Treatment

Current Opinion in Hepatitis C Treatment White Nights of Hepatology 2011 Current Opinion in Hepatitis C Treatment George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University

More information

PERSPECTIVES ON DRUGS Hepatitis C treatment for injecting drug users

PERSPECTIVES ON DRUGS Hepatitis C treatment for injecting drug users UPDATED 15. 5. 2015 PERSPECTIVES ON DRUGS Hepatitis C treatment for injecting drug users Transmitted through the sharing of needles, syringes and other injecting equipment, hepatitis C is the most common

More information

«I-Reivac» Un réseau d excellence pour la recherche clinique en vaccinologie

«I-Reivac» Un réseau d excellence pour la recherche clinique en vaccinologie «I-Reivac» Un réseau d excellence pour la recherche clinique en vaccinologie I-Reivac Pr Odile Launay Inserm, Université Paris Descartes, AP-HP, Hôpital Cochin, Paris F-CRIN, une infrastructure pour l

More information

Co-infected health-care workers

Co-infected health-care workers Co-infected health-care workers Y.Yazdanpanah Service Universitaire des Maladies Infectieuses et du Voyageur C.H. Tourcoing, Faculté de Médecine de Lille CNRS U362, Lille, France Co-infected health-care

More information

Telephone: 514-878-2691 Email: parent.nicole@rcgt.com

Telephone: 514-878-2691 Email: parent.nicole@rcgt.com NICOLE PARENT, RN PHD Telephone: 514-878-2691 Email: parent.nicole@rcgt.com CAREER PROFILE Nicole Parent, RN, PhD is a Senior Consultant in s Strategy and Performance Consulting Group. She is also a nurse

More information

HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain

HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening

More information

Vaccines Researches for the Future:

Vaccines Researches for the Future: ITMO Microbiologie et maladies infectieuses Vaccines Researches for the Future: The corevac initiative Pr Brigitte AUTRAN Institute Infection-Cancer-Immunity, UPMC, Paris Pr Jean François Delfraissy Institute

More information

Hepatitis C treatment update

Hepatitis C treatment update Hepatitis C treatment update Viral Hepatitis Workshop Hepatitis Foundation and Regional Public Health December 2013 Jeffrey S Wong Hepatitis C treatment Non-A non-b hepatitis History of HCV treatment Hutt

More information

New treatment options for HCV: implications for the Optimal Use of HCV Assays

New treatment options for HCV: implications for the Optimal Use of HCV Assays New treatment options for HCV: implications for the Optimal Use of HCV Assays Hans Orlent Dept. of Gastroenterology & Hepatology AZ Sint Jan Brugge-Oostende, Brugge This program is supported by educational

More information

Briefing Note: Hepatitis B & Hepatitis C. Summary:

Briefing Note: Hepatitis B & Hepatitis C. Summary: Briefing Note: Hepatitis B & Hepatitis C Summary: In Canada, hepatitis B and hepatitis C infections remain serious public health concerns due to high prevalence rates, high health care expenditures and

More information

Chronic infection with hepatitis C virus

Chronic infection with hepatitis C virus SPECIAL CONSIDERATIONS IN THE MANAGEMENT OF HIV/HCV COINFECTION Kenneth E. Sherman, MD, PhD* ABSTRACT Liver disease has emerged as a major cause of morbidity and mortality in patients infected with the

More information

Slide 1 HIV/ HCV Coinfected people: what are the specific concerns they face?

Slide 1 HIV/ HCV Coinfected people: what are the specific concerns they face? Slide 1 HIV/ HCV Coinfected people: what are the specific concerns they face? Marion Peters MD University of California San Francisco 2011 Slide 2 Special issues Effect of HIV on HCV Effects of HCV on

More information

Current & New Hepatitis C Meds on the Horizon

Current & New Hepatitis C Meds on the Horizon Current & New Hepatitis C Meds on the Horizon African Americans & Clinical Trials National Black Leadership Commission on AIDS May 28, 2014 Tracy Swan, Treatment Action Group Short for.. PEG-IFN pegylated

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy

More information

Cardiovascular Disease in AIDS

Cardiovascular Disease in AIDS Cardiovascular Disease in AIDS Giuseppe Barbaro - Franck Boccara (Eds) Cardiovascular Disease in AIDS Foreword by W. Rozenbaum 1 3 GIUSEPPE BARBARO Department of Medical Pathophysiology University La Sapienza

More information

Coinfezione HIV-HCV. Raffaele Bruno, MD. Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Coinfezione HIV-HCV. Raffaele Bruno, MD. Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy Coinfezione HIV-HCV Raffaele Bruno, MD This program is supported by educational grants from Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

More information

CURRICULUM VITAE 2012, March

CURRICULUM VITAE 2012, March CURRICULUM VITAE 2012, March OVERVIEW INFORMATION Name: MARHOUM EL FILALI Kamal Date and birthplace: July 16, 1958 in Casablanca, Sex: Male Nationality: Moroccan Contact Information: Business contact Personal

More information

Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH

Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH TREATMENT FAILURE AND PATTERNS OF GENOTYPIC DRUG RESISTANCE MUTATIONS AMONG HAART EXPERIENCED HIV-1 PATIENTS AT KCMC Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH

More information

A Proposal for Managing the Harvoni Wave June 22, 2015

A Proposal for Managing the Harvoni Wave June 22, 2015 A Proposal for Managing the Harvoni Wave June 22, 2015 Clinical Background Hepatitis C is an infectious disease caused by the Hepatitis C Virus (HCV) that damages the liver over time. The disease affects

More information

Cirrhosis and HCV. Jonathan Israel M.D.

Cirrhosis and HCV. Jonathan Israel M.D. Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment

More information

The question and answer session is not available after the live webinar.

The question and answer session is not available after the live webinar. 1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments

More information

Update on Hepatitis C. Sally Williams MD

Update on Hepatitis C. Sally Williams MD Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;

More information

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient

More information

London Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL

London Therapeutic Tender Implementation: Guidance for Clinical Use. 4 th June 2014 FINAL London Therapeutic Tender Implementation: Guidance for Clinical Use 4 th June 2014 FINAL Contents 3. General principles 4. Financial impact of therapeutic tendering for branded ARVs 5. London ARV algorithm:

More information

Goals of Therapy. Treatment Options for Hepatitis C. Patterns of Response. Progress in Hepatitis C Therapy

Goals of Therapy. Treatment Options for Hepatitis C. Patterns of Response. Progress in Hepatitis C Therapy Treatment Options for Hepatitis C Helen S. Te, M.D. Center for Liver Diseases University of Chicago Hospitals Chicago, Illinois Primary: To eliminate the virus Goals of Therapy Secondary: To decrease inflammation

More information

Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy

Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy London, UK, 3 February 2011 Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered

More information

VERTEX PHARMACEUTICALS INC / MA

VERTEX PHARMACEUTICALS INC / MA VERTEX PHARMACEUTICALS INC / MA FORM 8-K (Unscheduled Material Events) Filed 6/1/2005 For Period Ending 5/31/2005 Address 130 WAVERLY STREET CAMBRIDGE, Massachusetts 02139-4242 Telephone 616-577-6000 CIK

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following

More information

Writing Group. Dr Mark Nelson (Vice Chair) Prof Anna Maria Geretti. Dr Ranjababu Kulasegaram. Dr Adrian Palfreeman Dr Padmasayee Papineni

Writing Group. Dr Mark Nelson (Vice Chair) Prof Anna Maria Geretti. Dr Ranjababu Kulasegaram. Dr Adrian Palfreeman Dr Padmasayee Papineni BHIVA guidelines for the management of hepatitis viruses in adults infected with HIV 2013 Update September 2014: Consensus statement on the guidelines for treating hepatitis C in patients with HIV Further

More information

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment

More information

Guideline. Treatment of tuberculosis in patients with HIV co-infection. Version 3.0

Guideline. Treatment of tuberculosis in patients with HIV co-infection. Version 3.0 Guideline Treatment of tuberculosis in patients with HIV co-infection Version 3.0 Key critical points Co-infection with Tuberculosis (TB) and HIV is common in many parts of the world, especially sub-saharan

More information

Prior Authorization Policy

Prior Authorization Policy Prior Authorization Policy http://www.paramounthealthcare.com/providers Ribavirin Rebetol (ribavirin capsule or oral solution) Copegus (ribavirin tablet), Moderiba (ribavirin tablet), Ribasphere (ribavirin

More information

Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?

Patients with HCV and F1 and F2 fibrosis stage: treat now or wait? Liver International ISSN 1478-3223 REVIEW ARTICLE Patients with HCV and F1 and F2 fibrosis stage: treat now or wait? Mitchell L. Shiffman 1 and Yves Benhamou 2 1 Liver Institute of Virginia, Bon Secours

More information

boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd

boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

Treatment of Acute Hepatitis C

Treatment of Acute Hepatitis C Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Acute Hepatitis C Michael P. Manns, Andrej Potthoff, Elmar Jaeckel, Heiner Wedemeyer Hepatitis C Virus (HCV) infection is a common

More information

Positive impact of HCV treatment initiation on health outcomes in injecting drug users

Positive impact of HCV treatment initiation on health outcomes in injecting drug users Positive impact of HCV treatment initiation on health outcomes in injecting drug users Perrine ROUX, PhD Substance Use Research Center, Columbia University, NY Inserm U912, SE4S, Marseille Introduction

More information

UPDATE ON NEW HEPATITIS C MEDICINES

UPDATE ON NEW HEPATITIS C MEDICINES UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir

More information

Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS

Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for

More information

MEDICAL POLICY STATEMENT

MEDICAL POLICY STATEMENT MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements

More information

Curriculum Vitae Emmanuelle Nègre March 2015

Curriculum Vitae Emmanuelle Nègre March 2015 Curriculum Vitae Emmanuelle Nègre March 2015 Personal Details: Date of birth: June 25 th 1987 Nationality: French Marital status: Single Home Address: 5 rue Rivals 31 000 Toulouse France Tel.: +33.(0)6.76.79.01.31

More information

DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME

DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME Johan Neyts Rega Institute for Medical Research, University of Leuven, Belgium Johan.neyts@rega.kuleuven.be www.antivirals.be Pentalfa, 28

More information

Update on hepatitis C: treatment and care and future directions

Update on hepatitis C: treatment and care and future directions Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New

More information

The Respective Roles of Controlled Clinical Trials and Cohort Monitoring Studies in the Pre- and Postmarketing Assessment of Drugs

The Respective Roles of Controlled Clinical Trials and Cohort Monitoring Studies in the Pre- and Postmarketing Assessment of Drugs PHARMACOLOGIE CLINIQUE Thérapie 2005 Juil-Août; 60 (4): 345-349 0040-5957/05/0004-0345/$34.95/0 2005 Société Française de Pharmacologie The Respective Roles of Controlled Clinical Trials and Cohort Monitoring

More information

The following should be current within the past 6 months:

The following should be current within the past 6 months: EVALUATION Baseline Labs Obtain at time or prior to initial evaluation CBC with diff PT/INR CMP HCV Genotype (obtained PRIOR TO consult visit) HCV RNA (obtained PRIOR TO consult visit) Hep A IgG Hep BsAg,

More information

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Interferon,

More information

Frontier AIDS Education and Training Center

Frontier AIDS Education and Training Center Frontier AIDS Education and Training Center Vitamin D and HIV Subbulaxmi Trikudanathan, MD, MRCP, MMSc Division of Endocrinology, Metabolism and Nutrition University of Washington Medical Center Presentation

More information

HEPATITIS C TREATMENT GUIDELINES

HEPATITIS C TREATMENT GUIDELINES HEPATITIS C TREATMENT GUIDELINES Updated May 21, 2014 INSTRUCTIONS: 1. Review the posted Hepatitis C Treatment Guidelines document to validate that your patient meets the criteria for treatment. 2. Complete

More information

Curriculum vitae. Safy Zahid Kaddah. Assistant professor of chest diseases department, Cairo University.

Curriculum vitae. Safy Zahid Kaddah. Assistant professor of chest diseases department, Cairo University. Curriculum vitae Safy Zahid Kaddah Assistant professor of chest diseases department, Cairo University. The chest diseases department coordinate of the technical support office for projects and grants Kasr

More information

Vitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr

Vitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr Vitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr Stefan Pilz Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Austria Department

More information

New IDSA/AASLD Guidelines for Hepatitis C

New IDSA/AASLD Guidelines for Hepatitis C NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation

More information

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline

More information

Hepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm?

Hepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm? Hepatitis C David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham Substance Misuse Treatment in the West Midlands. How can we reduce harm? Birmingham October 19 th 2007 infection HCV Natural History

More information

Screening and Treatment for Hepatitis C in HIV Co-Infected Patients in Primary Care

Screening and Treatment for Hepatitis C in HIV Co-Infected Patients in Primary Care Screening and Treatment for Hepatitis C in HIV Co-Infected Patients in Primary Care Amanda Hutton Parrott, DPT, NP Carol Dawson Rose, PhD, RN, FAAN Roland Zepf, MS, RN, ACRN Patricia Ambrose, MS, RN Background

More information

Routine HIV Monitoring

Routine HIV Monitoring Routine HIV Monitoring Guideline of the HIV/AIDS Division at San Francisco General Hospital Statement of Guideline: Patients will be routinely evaluated and monitored for HIV parameters, antiretroviral

More information

In this study, the DCV+ASV regimen had low rates of discontinuation (5%) due to adverse events, and low rates of serious adverse events (5.

In this study, the DCV+ASV regimen had low rates of discontinuation (5%) due to adverse events, and low rates of serious adverse events (5. BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection An overall SVR 24 rate of 84.7 percent was

More information

NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)

NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with

More information

Le métier d'infectiologue en Europe. Bruno Hoen Université de Franche Comté CHU de Besançon EGI 14 janvier 2011

Le métier d'infectiologue en Europe. Bruno Hoen Université de Franche Comté CHU de Besançon EGI 14 janvier 2011 Le métier d'infectiologue en Europe Bruno Hoen Université de Franche Comté CHU de Besançon EGI 14 janvier 2011 Une définition européenne de l'infectiologie? Les infectiologues en Europe? Pas dans tous

More information

Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones

Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones 3 Executive Summary 4 Introduction 5 The

More information

Viral load testing. medical monitoring: viral load testing: 1

Viral load testing. medical monitoring: viral load testing: 1 medical monitoring: viral load testing: 1 medical monitoring: viral load testing Viral load testing medical monitoring: viral load testing: 2 Slide 1 Viral load The viral load test measures HIV in the

More information

HCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre

HCV/HIVCo-infection A case study by. Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV

More information

A study to Evaluate PPI s effect on vitamin D levels. Rani Hanna M.D., M.S. PGY-3 Joseph Grisanti, MD

A study to Evaluate PPI s effect on vitamin D levels. Rani Hanna M.D., M.S. PGY-3 Joseph Grisanti, MD A study to Evaluate PPI s effect on vitamin D levels Rani Hanna M.D., M.S. PGY-3 Joseph Grisanti, MD The sunshine vitamin Existed over 500 million years. Prehormone, not only a vitamin. Two major sources:

More information

EACS 2013. Dominique Braun Universitätsspital Zürich

EACS 2013. Dominique Braun Universitätsspital Zürich EACS 2013 Switch data Rilpivirine: Swing-trial Elvitegravir: Flamingo-trial Simplification Dual-Therapy: LPV/r + 3TC in the Gardel-trial Mono-Therapy: Darunavir/r mono in clinical setting Boceprevir/Telaprevir

More information

Monitoring of Treatment of viral hepatitis C

Monitoring of Treatment of viral hepatitis C Monitoring of Treatment of viral hepatitis C J.Boubaker Department of Gastroenterology La Rabta hospital Tunis-Tunisia Monitoring of Hepatitis C Treatment Aims of Monitoring : Evaluate Efficacy. Detect

More information